Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Rectal Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Lung Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms, Male 1Adenocarcinoma Of Esophagus 1

Interventions

Rituximab 45Cyclophosphamide 32fludarabine phosphate 28fludarabine 19ibrutinib 17Peripheral Blood Stem Cell Transplantation 17Lenalidomide 17venetoclax 13Mycophenolic Acid 10Cyclosporine 10acalabrutinib 9Whole-Body Irradiation 9Filgrastim 9obinutuzumab 7Bendamustine Hydrochloride 7Antilymphocyte Serum 7Radiotherapy 6Methotrexate 6Melphalan 6Prednisone 5Etoposide 5Busulfan 5zanubrutinib 4pirtobrutinib 4aldesleukin 4Vincristine 4Tacrolimus 4Indium 4Immunotherapy, Adoptive 4Granulocyte Colony-Stimulating Factor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Lymphocytic, Chronic, B-Cell × oblimersen × Clear all
NCT00021749 2009-11-13

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

Genta Incorporated

Phase 1/2 Completed
40 enrolled
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡